MK-2048

From Proteopedia

Jump to: navigation, search

The Investigational New Drug, MK-2048, (3oyj)

Better Known as: N/A

  • Marketed By: Merck & Co.
  • Major Indication: Human Immunodeficiency Virus Infection
  • Drug Class: Retroviral Integrase Inhibitor
  • Expected FDA Approval: N/A (Currently in Phase III trials)
  • Projected Sales: N/A
  • Importance: It is a second generation Retroviral Integrase inhibitor expected to be the next effective HIV treatment to come to market. Clinical trials reveal that it is superior to Raltegravir with a nearly 4 times longer inhibition period.
  • See Pharmaceutical Drugs for more information about other drugs and disorders.

Mechanism of Action

Retroviral Integrase is produced by the HIV retrovirus, enabling HIV to integrate its genetic material into the DNA of the infected cell. This integration step effectively transforms the infected cell into a permanent carrier of the viral genome, allowing the virus to persist and proliferate nearly without limit.[1] HIV retroviral integrase forms "intasomes" when it . The integrase domains interact extensively with the viral DNA, precisely within an active site, in close proximity to the predicted target DNA into which the viral DNA will be inserted. MK-2048 binds with great specificity to the HIV integrase active site. It orients itself in such a way as to displace the reactive viral DNA end from the active site almost completely. to residues Asp 128, Asp 185, & Glu 221 via strong interactions with magnesium ions and has extensive π-stacking interactions with the final two nucleotide rings on one viral DNA strand. This disruption prevents the viral DNA from interacting with the target DNA, preventing integration and HIV proliferation.[2][3]

Pharmacokinetics

Retroviral Integrase Inhibitor Pharmacokinetics
Parameter Raltegravir Elvitegravir MK-2048
Tmax (hr) 1.8 2-4 N/A
Cmax (ng/ml) 4253 2070 N/A
Bioavailability (%) 32 ~30 N/A
Protein Binding (%) 83 N/A N/A
T1/2 (hr) 10.8 7.6 N/A
AUC (ng/ml/hr) 10168 21200 N/A
Dosage (mg) 400 150 N/A
Metabolism Hepatic - (UGT1A1) Hepatic - (CYP3A4) N/A

For Pharmacokinetic Data References, See: References

References

  1. Savarino A. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert Opin Investig Drugs. 2006 Dec;15(12):1507-22. PMID:17107277 doi:10.1517/13543784.15.12.1507
  2. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature. 2010 Mar 11;464(7286):232-6. Epub 2010 Jan 31. PMID:20118915 doi:10.1038/nature08784
  3. Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, Cherepanov P. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A. 2010 Oct 28. PMID:21030679 doi:10.1073/pnas.1010246107


Proteopedia Page Contributors and Editors (what is this?)

David Canner

Personal tools